Evolution of the Average Target: Black Diamond Therapeutics, Inc.

Evolution of the Average Target - Black Diamond Therapeutics, Inc.

Evolution of the Target Price: Black Diamond Therapeutics, Inc.

Evolution of the Target Price - Black Diamond Therapeutics, Inc.

Changes in Analyst Recommendations: Black Diamond Therapeutics, Inc.

17d3.www0dQw8yTu15jY8tnqSY5eqHunobD_KydaQQboX9cY.kHoERTlfjHrA3lxegUzfAcDvdqbZGEeCu67JLP5yh4eLWUBMOF2lA_aHew~dd7398e25f6713e6a65fb8df2979a310
17/03 Wedbush Lifts Price Target on Black Diamond Therapeutics to $14 From $13, Keeps Outperform Rating MT
07/08/25 Black Diamond Therapeutics Q2 net loss narrows as costs drop RE
07/03/25 Wedbush Adjusts Black Diamond Therapeutics Price Target to $11 From $16, Maintains Outperform Rating MT
31/07/24 Raymond James Initiates Black Diamond Therapeutics at Outperform MT
16/05/24 HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating MT
09/04/24 Wedbush Adjusts Price Target on Black Diamond Therapeutics to $16 From $10 After Market Confirmation for Drug, Maintains Outperform Rating MT
14/07/23 Piper Sandler Initiates Black Diamond Therapeutics With Overweight Rating, $11 Price Target MT
30/06/23 Stifel Upgrades Black Diamond Therapeutics to Buy From Hold, Adjusts Price Target to $10 From $2 MT
28/06/23 HC Wainwright Upgrades Black Diamond Therapeutics to Buy From Neutral, Price Target is $11 MT
28/06/23 Wedbush Upgrades Black Diamond Therapeutics to Outperform From Neutral, Adjusts Price Target to $10 From $3 MT
13/05/22 Wedbush Lowers Price Target for Black Diamond Therapeutics to $3 From $4, Maintains Neutral Rating MT
01/04/22 Berenberg Bank Adjusts Black Diamond Therapeutics Price Target to $16 From $34, Maintains Buy Rating MT
29/03/22 Wedbush Downgrades Black Diamond Therapeutics to Neutral From Outperform, Citing BDTX-1535 Timeline, Likely BDTX-189 Discontinuation, 'Tough' Financing Environment; PT to $4 From $22 MT
22/03/22 HC Wainwright Downgrades Black Diamond Therapeutics to Neutral From Buy MT
19/03/22 Stifel Adjusts Price Target on Black Diamond Therapeutics to $4 From $10, Reiterates Hold Rating MT
30/09/21 Black Diamond Therapeutics : Stifel Starts Black Diamond Therapeutics at Hold With $10 Price Target MT
18/08/21 Black Diamond Therapeutics : Wedbush Lowers PT for Black Diamond Therapeutics to $22 From $48 Following BDTX-189 Data, Reiterates Outperform Rating MT
17/08/21 Black Diamond Therapeutics : Berenberg Bank Adjusts Black Diamond Therapeutics PT to $34 From $58, Maintains Buy Rating MT
21/05/21 Black Diamond Therapeutics : Wedbush Removes Outperform-Rated Black Diamond Therapeutics From Best Ideas List; Price Target is $48 MT
30/03/21 Black Diamond Therapeutics : Wedbush Adds Outperform-Rated Black Diamond Therapeutics to Best Ideas List; Price Target is $48 MT
26/03/21 Black Diamond Therapeutics : Wedbush Adjusts Price Target on Black Diamond Therapeutics to $48 From $45, Keeps Outperform Rating MT
07/01/21 Black Diamond Therapeutics : Wedbush Starts Black Diamond Therapeutics at Outperform With $45 Price Target MT
25/11/20 Black Diamond Therapeutics : Berenberg Starts Black Diamond Therapeutics at Buy With $58 Price Target MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+739.69%
+43.71%
+19.37%
+11.58%
+20.93%
+26.92%
+30.99%
+70.4%
+20.93%
+37.4%
Average +102.19%
Weighted average by Cap. +30.40%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.310USD
Average target price
11.00USD
Spread / Average Target
+739.69%
High Price Target
14.00USD
Spread / Highest target
+968.70%
Low Price Target
8.000USD
Spread / Lowest Target
+510.69%

Analyst Consensus Detail

Analyst consensus - Black Diamond Therapeutics, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Black Diamond Therapeutics, Inc.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Black Diamond Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. BDTX Stock
  4. Consensus Black Diamond Therapeutics, Inc.